Our Senior Director of Clinical Development, Tyrell Simkins, D.O., Ph.D., will present the poster, “ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regulatory T Cells and Neuroinflammation in ALS,” on Wednesday, June 3 at 4:45 PM ET at the 5th ALS Drug Development Summit.
For more information: https://t.co/nDJ1miXHxt
$COYA Coya Therapeutics announced they will present P2 Amyotrophic Lateral Sclerosis results on 2026-06-03 for COYA-302
More Info: https://t.co/53XthtXVQX
Patients with #ALS treated with Coya 302 saw increases in regulatory T cells, less #inflammation and slower disease progression, said Dr. Fred Grossman, president of @CoyaTx.
https://t.co/amwPJrvYWe
Coya Therapeutics’ experimental injection therapy COYA 302 has been granted fast track designation by the U.S. FDA for treating ALS. https://t.co/Lb08LaepZN
#ALS#ALSNewsToday#Bionews#ALSCommunity
Coya is pleased to announce that the FDA has granted Fast Track Designation to COYA 302 for the treatment of #ALS.
Fast Track Designation is intended to facilitate the development and expedite the review of therapies for serious conditions with significant unmet medical need. This designation underscores the urgent need for new treatment options for people living with ALS and supports the continued advancement of COYA 302 through the regulatory process.
For more details: https://t.co/MoSGPIvij4
$COYA
$COYA +nan% today
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
More Info: https://t.co/53XthtXVQX
$COYA - Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
News & Disclaimer
https://t.co/n5e27W6kxX
$COYA — Coya Therapeutics' stock has risen following the company's disclosure of a study showing that COYA 302 elevated three specific biomarkers in individuals with ALS, contrasting with control subjects.
@BeckyQuick@Kramer_Katie Hereditary gene mutations is something that has affected my family. Thankfully it’s not common I would not wish it on anyone. Knowing my kids could get this stinks
Coya today announced the acceptance of the clinical trial application from Health Canada to proceed with the COYA 302 ALSTARS trial for #ALS. This allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers.
For more details: https://t.co/N5ZZaBvkGN
(NASDAQ: $COYA)
Coya Therapeutics has launched the ALSTARS Phase 2 trial of COYA 302 in ALS. The 120-patient study will assess safety and efficacy across 25 sites in the U.S. and Canada, with a blinded extension to evaluate long-term outcomes. A key step toward addressing one of the toughest unmet needs in neurodegeneration.
@CoyaTx
https://t.co/NoBg4iPKGh